Dr. Mitchell J. Goff, M.D.
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
4400 S 700 E Ste 200
Salt Lake City, UT 84107
Who else practices at this address →
Salt Lake County includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Medical College of Wisconsin (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 689
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Medical College of Wisconsin
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
UT license 7540912-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Mark's Hospital Salt Lake City, UT
Medical groups
- Eye Institute of Utah Inc (10 clinicians)
- Rocky Mountain Retina Consultants (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 689
- Services billed
- 24,076
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 8,700 | 34 |
| Injection, aflibercept, 1 mg | 2,714 | 334 |
| Imaging of retina | 2,124 | 847 |
| Injection of drug into eye | 1,893 | 472 |
| Established patient office or other outpatient visit, 30-39 minutes | 923 | 601 |
| Injection, ranibizumab, 0.1 mg | 870 | 42 |
| Unclassified drugs | 428 | 213 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 332 | 33 |
| Established patient office or other outpatient visit, 20-29 minutes | 250 | 204 |
| Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 250 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Salt Lake City, UT | 92 |
| Prednisolone Acetate Other prescribers in Salt Lake City, UT | 43 |
| Ketorolac Tromethamine Other prescribers in Salt Lake City, UT | 20 |
| Simbrinza (brinzolamide/brimonidine tart) Other prescribers in Salt Lake City, UT | 17 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Salt Lake City, UT | 15 |
| Timolol Maleate Other prescribers in Salt Lake City, UT | 15 |
| Rocklatan (netarsudil mesylat/latanoprost) Other prescribers in Salt Lake City, UT | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 43 payments worth $9,189 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $5,970 |
|---|---|
| Regeneron Pharmaceuticals, Inc. | $1,410 |
| Astellas Pharma US Inc | $1,257 |
| Harrow Eye, LLC | $355 |
| Genentech USA, Inc. | $94.27 |
| AbbVie Inc. | $65.47 |
| Ani Pharmaceuticals, Inc. | $35.68 |
| Compensation for services other than consulting (speaking, faculty) | $6,447 |
|---|---|
| Consulting Fee | $1,410 |
| Food and Beverage | $1,332 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. May 9, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $3,290 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $2,407 |
| Regeneron Pharmaceuticals, Inc. May 16, 2025 | Consulting Fee EYLEA HD · OPHTHALMOLOGY | $1,410 |
| Astellas Pharma US Inc Jun 22, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $95,121 in research payments for these studies, mostly to the institutions running them.
- Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - Port Delivery System for Ranibizumab
Genentech, Inc. - Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degener…
AbbVie Inc. - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - Unity VCS Vit Ret Claims Study
Alcon Research LLC - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)
AbbVie Inc. - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.